GLP-1 warnings on TikTok: separating real risks from noise

What did @realdrbae actually say?

The core claim is straightforward: injecting into the same spot repeatedly causes lipohypertrophy, a buildup of thickened, scarred tissue under the skin. According to the creator, this makes drug absorption "less predictable," which can make it seem like your GLP-1 stopped working when it actually hasn't. The fix offered is rotating between the left abdomen, right abdomen, left thigh, and right thigh. The creator also clarifies, usefully, that this advice is about preventing lipohypertrophy specifically, not about managing side effects through site selection. That's a reasonable distinction to make, and they made it clearly.

The video doesn't push any specific product, doesn't prescribe doses, and doesn't make disease-cure claims. From a basic harm-reduction standpoint, this is consumer health education, not dangerous misinformation.

Does the science back this up?

Yes, on the core claim. Lipohypertrophy from repeated injection into the same site is well-documented in insulin-dependent diabetes literature, and the mechanism applies to subcutaneous GLP-1 injections as well. The absorption disruption is real.

The strongest evidence base comes from insulin therapy research. Blanco et al. (2013, Diabetes Care) found lipohypertrophy in 49.1% of insulin-injecting patients, and those patients had significantly higher HbA1c variability and unexpected hypoglycemic episodes, consistent with erratic absorption. The physiological reason is that lipohypertrophic tissue is poorly vascularized, so drug uptake slows and becomes inconsistent rather than absent entirely.

For GLP-1 receptor agonists specifically, the direct evidence is thinner. Most of what we know is extrapolated from subcutaneous insulin data and general pharmacokinetic principles for subcutaneous biologics. The FDA-approved prescribing information for semaglutide (Ozempic, Wegovy) does recommend rotating injection sites, which reflects clinical consensus even where randomized trial data for GLP-1s specifically is limited. The creator's claim holds up under that standard.

What did they get wrong (or right)?

They got the main point right. Rotating injection sites is standard clinical guidance and is backed by solid mechanistic reasoning and strong analogous evidence from insulin research.

Where they overreach slightly: calling lipohypertrophy "thick and fatty tissue" is a reasonable lay description, but the creator uses the terms "scar tissue" and "thick and scar tissue" somewhat interchangeably. These are not the same thing. Lipohypertrophy is primarily a hypertrophy of adipocytes and connective tissue, not classical fibrotic scar formation. The clinical consequences are similar in terms of absorption, but the biology is different. It's a minor imprecision, not a dangerous one, but worth noting.

The claim that non-rotating causes a visible "bulge in your lower abdomen" is real but overstated as a universal. Lipohypertrophy is palpable in many cases before it's visually obvious, and it depends heavily on body composition, injection technique, and frequency. Presenting it as a consistent cosmetic outcome may be exaggerated.

The side-effects clarification at the end is actually a credit to the creator. Telling viewers the rotation advice is site-specific to absorption, not symptom management, is accurate and responsible.

What should you actually know?

Rotation matters, and most patients don't do it consistently enough. The approved injection sites for semaglutide include the abdomen, thigh, and upper arm. Adding the upper arm to the rotation, which the creator doesn't mention, gives you more options and reduces frequency at each site.

Here's the practical part: rotating within a region matters too, not just between regions. Injecting in slightly different spots within your abdomen counts. Baudoin et al. (2016, Diabetes Research and Clinical Practice) found that even patients who self-reported rotating sites often had lipohypertrophy because they weren't varying their exact injection point enough.

If you've developed lipohypertrophy, the standard clinical recommendation is to avoid that site entirely for an extended period to allow tissue recovery. There is no approved drug to reverse it. The tissue can partially normalize over months, but this varies.

And if your GLP-1 genuinely seems to have plateaued in effect, lipohypertrophy is one possible explanation but not the only one. Weight loss plateaus on GLP-1s have multiple mechanisms, including metabolic adaptation and changes in appetite signaling over time. Don't assume site problems are the whole answer without talking to your prescriber.